Thursday, the England-based rare disease drugmaker Cycle Pharmaceuticals revealed an $8-per-share offer for Vanda, representing a total buyout offer of $466 million. In a statement (PDF), Vanda ...

Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the ...

When Vanda requested an additional two weeks to review ... delivering drug treatments and product support to the underserved rare disease patient community, and the healthcare professionals ...

Mysuru is not only famous for its festivals and palaces but also for its rare animals and plants From the slow moving Indian ...

WASHINGTON and SAN DIEGO, Feb. 3, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced ...

It was the second time in four months that Vanda swatted away a takeover bid from Cycle, which specializes in rare diseases. “Vanda’s board of directors carefully reviewed the second proposal ...

for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S). Vanda Logo (PRNewsfoto/Vanda Pharmaceuticals Inc.) "More than two decades after the human ...

Vanda has insisted it will continue to seek approval ... and the push to expand therapy reach in rare blood cancers.

VCA-894A for Charcot-Marie-Tooth disease, Type 2S (CMT2S): Vanda received Orphan Drug Designation from the FDA for VCA-894A, a treatment for CMT2S, a rare subtype of Charcot-Marie-Tooth disease.

A man has been arrested by Aizawl police for allegedly stealing rare and protected orchid species from the deserted Assam Rifles battalion headquarters complex in the city.

Vanda announced that the FDA has granted Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide-based JAK2 inhibitor for the treatment of polycythemia vera, a form of a rare ...